Developing new drugs to treat serious disorders of the central nervous system

News & Events

Tweets

AutifonyLtd @AutifonyLtd
Autifony announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing… https://t.co/oeGgN4ooWG
Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator, please take… https://t.co/A1hedx6tYy
Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic appro… https://t.co/xOlDJ1kTe9
Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image